The MD Anderson Symptom Inventory for acute myeloid leukemia/myelodysplatic syndrome (MDASI-AML/MDS) is a disease site-specific module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-AML/MDS also assesses 4 symptom items specific to acute myeloid leukemia and myelodysplastic syndrome:
- feeling of malaise (not feeling well)
- diarrhea (loose stools)
- muscle weakness
- skin problems
Order the MDASI-AML/MDS
To use the MDASI-AML/MDS in a publication or clinical or research
trial, you must obtain permission by filling out our order form and
you must comply with the copyright. Fees may apply.
Every MDASI Module Contains...
All 13 MDASI core symptoms
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
All 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
- Purpose: To assess the severity of multiple symptoms related to AML/MDS and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by AML/MDS and their treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
- Time required: Five minutes
- Scoring: Please see the MDASI User's Guide
- Reliability: Cronbach alpha reliability ranges from 0.88 to 0.91
Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122(5): 641-7, 2013.
Williams LA, Ahaneku H, Cortes JE, et al. Comparison of symptom burden in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [abstract]. American Society of Hematology (ASH) 56th Annual Meeting and Exposition, San Francisco CA, Dec 6-9, 2014. Blood 124(21), 2014; Abstract # 2652.